Confino-Cohen Ronit, Goldberg Arnon
Allergy and Clinical Immunology Unit, Meir General Hospital, Kfar Saba, Israel.
J Child Adolesc Psychopharmacol. 2005 Aug;15(4):703-5. doi: 10.1089/cap.2005.15.703.
Methylphenidate is a cornerstone of attention-deficit/hyperactivity disorder (ADHD) treatment. Cutaneous adverse reactions resulting from methylphenidate may prohibit its usage. We sought a way to continue this therapy in a patient who developed a rash twice following methylphenidate administration.
In a desensitization protocol, methylphenidate was given in increasing doses, 30 minutes apart, over 10 days, until the therapeutic dose was reached and was continued regularly thereafter.
No adverse reactions developed during the desensitization period or during the 6- month follow-up.
In nonlife threatening cutaneous adverse reactions to methylphenidate, a desensitization protocol may enable the continued, safe administration of this drug.
哌甲酯是治疗注意力缺陷多动障碍（ADHD）的基石。哌甲酯引起的皮肤不良反应可能会妨碍其使用。我们寻求一种方法，以便在一名服用哌甲酯后出现两次皮疹的患者中继续进行这种治疗。
在脱敏方案中，哌甲酯以递增剂量给药，每隔30分钟一次，持续10天，直至达到治疗剂量，此后定期持续给药。
在脱敏期或6个月的随访期间均未出现不良反应。
对于哌甲酯引起的非危及生命的皮肤不良反应，脱敏方案可能使该药物得以持续、安全地给药。
